Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients

被引:10
作者
Xiang, Hongping [1 ,2 ]
Zhou, Hong [1 ,2 ]
Zhang, Jing [3 ]
Sun, Yongfeng [3 ]
Wang, Yirong [4 ]
Han, Yong [1 ,2 ]
Cai, Jie [3 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Peoples R China
[2] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China
[4] Third Peoples Hosp Chengdu, Dept Pharm, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
mycophenolic acid; pharmacokinetics; therapeutic drug monitoring; limited sampling strategy; heart transplantation; BILIARY-EXCRETION; CYCLOSPORINE-A; PHARMACOKINETICS; MOFETIL; TACROLIMUS; KIDNEY; LIVER; BIOAVAILABILITY; POSTTRANSPLANT; POLYMORPHISMS;
D O I
10.3389/fphar.2021.652333
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: With the increasing use of mycophenolic acid (MPA) formulations in organ transplantation, the need for personalized immunosuppressive therapy has become well recognized based on therapeutic drug monitoring (TDM) for avoidance of drug-related toxicity while maintaining efficacy. Few studies have assessed area under the 12 h concentration-time curve of MPA (MPA-AUC(0-12h)) in heart transplant recipients who received mycophenolate mofetil (MMF) dispersible tablets (MMFdt). The aim of the study was to investigate the pharmacokinetics (PK) of MMFdt combined with tacrolimus and further to develop a practical method for estimation of MPA-AUC(0-12h) using a limited sampling strategy (LSS). Methods: A prospective study in a single center was performed in patients who continuously administrated with MMFdt or MMF capsule (MMFc) for at least 7 days after cardiac transplantation from 2018 to 2020. A total of 48 Chinese adult heart transplant recipients were enrolled. Blood samples were collected before and 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 12 h after MMF administration. The validated high-performance liquid chromatography combined with tandem mass spectrometry method was used to measure MPA concentrations. Non-compartmental pharmacokinetic (PK) analysis was applied to calculate the data obtained from individual recipients by WinNonlin. LSS models were developed for MPA-AUC(0-12h) prediction with multivariate stepwise regression analysis. Results: A large inter-individual variability was observed in AUC(0-12h), T-max, C-max, MRT0-12h, t(1/2) and CL/F after multiple dosing of MMFdt. However, no significant differences were observed between main PK parameters of MMFdt and MMFc. The best estimation of MPA-AUC(0-12h) was achieved with four points: MPA-AUC(0-12h) = 8.424 + 0.781 x C-0.5 + 1.263 x C-2 + 1.660 x C-4 + 3.022 x C-6 (R (2) = 0.844). The mean prediction error (MPE) and mean absolute prediction error (MAPE) of MPA-AUC(0-12h) were 2.09 +/- 14.05% and 11.17 +/- 8.52%, respectively. Both internal and external validations showed good applicability for four-point LSS equation. Conclusion: The results provide strong evidence for the use of LSS model other than a single time-point concentration of MPA when performing TDM. A four-point LSS equation using the concentrations at 0.5, 2, 4, 6 h is recommended to estimate MPA-AUC(0-12h) during early period after transplantation in Chinese adult heart transplant recipients receiving MMFdt or MMFc. However, proper internal and external validations with more patients should be conducted in the future.
引用
收藏
页数:12
相关论文
共 61 条
[1]   Mycophenolate mofetil and its mechanisms of action [J].
Allison, AC ;
Eugui, EM .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :85-118
[2]   Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients [J].
Armstrong, VW ;
Tenderich, G ;
Shipkova, M ;
Parsa, A ;
Koerfer, R ;
Schröder, H ;
Oellerich, M .
THERAPEUTIC DRUG MONITORING, 2005, 27 (03) :315-321
[3]   Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients [J].
Baraldo, M ;
Isola, M ;
Feruglio, MT ;
Francesconi, A ;
Franceschi, L ;
Tursi, V ;
Livi, U ;
Furlanut, M .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (05) :2240-2243
[4]   Immunosuppression with mycophenolic acid: One size does not fit all [J].
Bennett, WM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09) :2414-2416
[5]   The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes [J].
Bowalgaha, K ;
Miners, JO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) :605-609
[6]   Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review [J].
Bruchet, Nicole K. ;
Ensom, Mary H. H. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (09) :1079-1097
[7]   Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration [J].
Bullingham, R ;
Monroe, S ;
Nicholls, A ;
Hale, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (04) :315-324
[8]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[9]  
Bullingham RES, 1996, TRANSPLANT P, V28, P925
[10]   Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients [J].
Cai, W. ;
Cai, Q. ;
Xiong, N. ;
Qin, Y. ;
Lai, L. ;
Sun, X. ;
Hu, Y. .
TRANSPLANTATION PROCEEDINGS, 2018, 50 (05) :1298-1304